Accueil   Diary - News   All news Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH

Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH

 

 

  • The Phase 2a program will include two separate studies
  • Phase 2a efficacy and safety study for PXL770 is underway with data results anticipated 1H 2020
  • Pharmacokinetic (PK)/pharmacodynamic (PD) study for PXL770 is expected to initiate 2Q 2019 with results anticipated 2H 2019

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced initiation of the Phase 2a program for PXL770, a direct adenosine monophosphate-activated protein kinase activator (AMPK), for the treatment of NASH.

 

 

Read the press release